SCHEMBL9747177

SCHEMBL9747177

O=CCCC(=O)c1ccccn1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 9/20 0.55
WNT3A P56704 7/20 0.55
CES2 O00748 1/20 0.52
CES1 P23141 1/20 0.52
LMNA P02545 1/20 0.50
NAPRT Q6XQN6 1/20 0.50
P4HTM Q9NXG6 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ALDH1A1 P00352 1/20 0.48
GRM4 Q14833 1/20 0.47
KMT2A Q03164 2/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
GPR52 Q9Y2T5 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
GSK3B P49841 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19287209 0.90 CTNNB1 (0.53) CTNNB1WNT3ACES2CES1LMNA
SCHEMBL2470002 0.85 CTNNB1 (0.71) CTNNB1WNT3ACES2CES1LMNA
SCHEMBL30695014 0.83 CES2 (0.58) CTNNB1WNT3ACES2CES1LMNA
SCHEMBL225566 0.81 CES2 (0.55) CTNNB1WNT3ACES2CES1LMNA
SCHEMBL30609612 0.81 CTNNB1 (0.63) CTNNB1WNT3ACES2CES1LMNA
SCHEMBL4743860 0.81 CTNNB1 (0.63) CTNNB1WNT3ACES2CES1LMNA
SCHEMBL6709434 0.79 CTNNB1 (0.60) CTNNB1WNT3ACES2CES1LMNA
SCHEMBL27581934 0.78 CTNNB1 (0.51) CTNNB1WNT3ACES2CES1LMNA
SCHEMBL6197288 0.78 CTNNB1 (0.58) CTNNB1WNT3ACES2CES1LMNA
SCHEMBL30579595 0.78 CTNNB1 (0.63) CTNNB1WNT3ACES2CES1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0192554-B1 PEPTIDE DERIVATIVES INHIBITING RENIN AND ACID PROTEASES SANOFI (FR) 1992-01-02 EP claimed
EP-0211744-B1 PEPTIDIC AMINO-ALCOHOL DERIVATIVES CONTAINING A TETRA-SUBSTITUTED CARBON ATOM, INHIBITORS OF RENIN AND OF ACID PROTEASES, PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS SANOFI (FR) 1991-12-04 EP claimed
EP-0193445-B1 PEPTIDE DERIVATIVES, PEPSTATIN ANALOGUES, RENIN AND ACID-PROTEASE INHIBITORS SANOFI (FR) 1990-05-09 EP claimed
US-4840935-A Peptide amino-alcohol derivatives containing a tetrasubstituted carbon atom, inhibiting renin and acid proteases, process for obtention and therapeutical use SANOFI (FR) 1989-06-20 US claimed
US-11396501-B2 Heteroaryl compounds as CXCR4 inhibitors, composition and method using the same CGENETECH (SUZHOU, CHINA) CO., LTD. (CN) 2022-07-26 US disclosed
EP-3687540-A1 HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME CGeneTech (Suzhou, China) Co., Ltd. (CN) 2020-08-05 EP disclosed
US-20200239439-A1 HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2020-07-30 US disclosed
US-20200239439-A1 HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2020-07-30 US disclosed
WO-2019060860-A1 HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2019-03-28 WO disclosed
WO-2019060860-A1 HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2019-03-28 WO disclosed
US-20110212053-A1 PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS PROGENICS PHARMACEUTICALS, INC. 2011-09-01 US disclosed
US-4840935-A Peptide amino-alcohol derivatives containing a tetrasubstituted carbon atom, inhibiting renin and acid proteases, process for obtention and therapeutical use SANOFI (FR) 1989-06-20 US disclosed
US-4746648-A HYPOTENSIVE, ANTIULCER Sanofi, Institut National de la Recherche Medicale (FR) 1988-05-24 US disclosed
US-4725580-A ARTERIAL TENSION SANOFI (FR) 1988-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11396501-B2 Heteroaryl compounds as CXCR4 inhibitors, composition and method using the same CXCR4, CXCL12, CXCR1 CTNNB1 137/4885WNT3A 362/4885CES2 1347/4885
US-20110212053-A1 PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS PIK3CA, AKT1, PIK3R5 CTNNB1 1635/4885WNT3A 1415/4885CES2 3192/4885
US-20200239439-A1 HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME CXCR4, CXCL12, CXCR1 CTNNB1 137/4885WNT3A 362/4885CES2 1347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.